-
公开(公告)号：US11339124B2
公开(公告)日：2022-05-24
申请号：US16967871
申请日：2019-02-05
发明人： Peter Vandenabeele , Tom Vanden Berghe , Koen Augustyns , Sam Hofmans , Pieter Van Der Veken , Lars Devisscher
IPC分类号： C07C311/39 , C07D227/02 , C07D295/027 , C07D221/00 , C07D241/04 , C07D227/04
摘要： The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and/or oxytosis for the treatment of stroke, myocardial infarction, diabetes, sepsis, the prevention of transplant rejection, neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, dementia with Lewy bodies and Friedreich's ataxia. The present invention further relates to pharmaceutical compositions of these compounds and discloses methods for making the compounds and the corresponding intermediate.
-
公开(公告)号：US09862678B2
公开(公告)日：2018-01-09
申请号：US15525480
申请日：2015-11-16
发明人： Peter Vandenabeele , Tom Vanden Berghe , Koen Augustyns , Jurgen Joossens , Pieter Van Der Veken , Sam Hofmans
IPC分类号： C07C311/39 , C07C311/40 , C07D295/26 , C07D213/38 , C07D239/26
CPC分类号： C07C311/39 , C07C311/40 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/42 , C07C2603/74 , C07D213/38 , C07D239/26 , C07D295/26
摘要： This disclosure relates to a novel class of compounds having the structure of formula I as defined herein and pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. This disclosure also comprises methods of treating a subject by administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof to the subject. These compounds are useful for the conditions disclosed herein. This disclosure further comprises methods for making the compounds of formula I and corresponding intermediates.
-
3.发明申请TARGETING OF INTERLEUKIN-1 AND -18 SIGNALING IN TREATMENT OF SEPTIC SHOCK 有权白细胞介素-1和-18指征治疗分裂性疾病的指标公开(公告)号：US20160331837A1
公开(公告)日：2016-11-17
申请号：US15111374
申请日：2015-01-15
申请人： VIB VZW , UNIVERSITEIT GENT
IPC分类号： A61K39/395 , C07K16/24 , C07K16/28 , A61K38/20
CPC分类号： A61K39/3955 , A61K38/17 , A61K38/1793 , A61K38/20 , A61K2039/505 , A61K2039/507 , C07K16/244 , C07K16/2866 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to the inactivation of interleukin-1 and interleukin-18 signaling in treatment of inflammation and septic shock. More specifically, it relates to a sequential or simultaneous application of both an interleukin-1 receptor antagonist and an interleukin-18 antibody. In one preferred embodiment, a combination treatment of an IL-1 receptor antagonist and an IL-18 antibody is used.
摘要翻译： 本发明涉及白细胞介素-1和白细胞介素-18信号在治疗炎症和败血性休克中的失活。 更具体地，本发明涉及白细胞介素-1受体拮抗剂和白细胞介素-18抗体的连续或同时应用。 在一个优选实施方案中，使用IL-1受体拮抗剂和IL-18抗体的组合治疗。
-
公开(公告)号：US09919048B2
公开(公告)日：2018-03-20
申请号：US15111374
申请日：2015-01-15
申请人： VIB VZW , UNIVERSITEIT GENT
CPC分类号： A61K39/3955 , A61K38/17 , A61K38/1793 , A61K38/20 , A61K2039/505 , A61K2039/507 , C07K16/244 , C07K16/2866 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to the inactivation of interleukin-1 and interleukin-18 signaling in treatment of inflammation and septic shock. More specifically, it relates to a sequential or simultaneous application of both an interleukin-1 receptor antagonist and an interleukin-18 antibody. In one preferred embodiment, a combination treatment of an IL-1 receptor antagonist and an IL-18 antibody is used.
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
